* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
Today, Onward Opportunities (ONWD.L), the investment company targeting opportunities in UK smaller companies, moved from AIM to the Main Market.
Delistings:
None
What’s baking in the oven?
Potential IPOs:***
15th April: Rosebank Industries (ROSE.L) will move from AIM to the equity shares (commercial companies) (ESCC) category of the Official List of the FCA and to trading on the main market for listed securities of the London Stock Exchange on 1 May 2026. The last day of trading on AIM is therefore expected to be 30 April. Rosebank does not intend to raise any funds or offer any new Ordinary Shares in connection with Admission. The Company anticipates inclusion in the next Quarterly Review of the FTSE 250 Index, although inclusion remains subject to review by FTSE Russell.
13th April: EDX Medical (AQSE:EDX) which develops digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announced its intention to move to AIM from AQSE. No new capital is to be raised on Admission and the anticipated market capitalisation is £44.28m. Expected Admission date of 13th May.
1st April: Oscillate (AQSE: SRVL), the Company focused on building an independent copper and future metals developer, announced that further to the announcement on 9 February of the conditional acquisition of Kalahari Copper, it has conditionally completed an equity fundraising of £2.9m and plans to move to AIM from AQSE with a market cap of £7.6m. Net proceeds of the Fundraising will allow for the advancement of the Company's proposed exploration assets in Namibia and Botswana. In addition, the Company will change its name to Serval Resources. Admission to AIM is expected to occur on 27 April.
20th February: Wildcat Petroleum (WCAT.L) announced its plans to cancel its Main Market listing and move to the Aquis Growth Market. In parallel with the proposed cancellation, the Board intends to pursue opportunities in the gold sector, with a view to developing the Company as an African-based gold processing business. Timing TBC.
Market Movers:***
15th April: Rosebank Industries (ROSE.L) will move from AIM to the equity shares (commercial companies) (ESCC) category of the Official List of the FCA and to trading on the main market for listed securities of the London Stock Exchange on 1 May 2026. The last day of trading on AIM is therefore expected to be 30 April. Rosebank does not intend to raise any funds or offer any new Ordinary Shares in connection with Admission. The Company anticipates inclusion in the next Quarterly Review of the FTSE 250 Index, although inclusion remains subject to review by FTSE Russell.
13th April: EDX Medical (AQSE:EDX) which develops digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announced its intention to move to AIM from AQSE. No new capital is to be raised on Admission and the anticipated market capitalisation is £44.28m. Expected Admission date of 13th May.
1st April: Oscillate (AQSE: SRVL), the Company focused on building an independent copper and future metals developer, announced that further to the announcement on 9 February of the conditional acquisition of Kalahari Copper, it has conditionally completed an equity fundraising of £2.9m and plans to move to AIM from AQSE with a market cap of £7.6m. Net proceeds of the Fundraising will allow for the advancement of the Company's proposed exploration assets in Namibia and Botswana. In addition, the Company will change its name to Serval Resources. Admission to AIM is expected to occur on 27 April.
20th February: Wildcat Petroleum (WCAT.L) announced its plans to cancel its Main Market listing and move to the Aquis Growth Market. In parallel with the proposed cancellation, the Board intends to pursue opportunities in the gold sector, with a view to developing the Company as an African-based gold processing business. Timing TBC
Banquet Buffet****
Alumasc Group 222.5p £80.0m (ALU.L)
The premium sustainable building products, systems and solutions Group, updated on trading for the third quarter of its financial year ending 30 June 2026. The Group anticipates a materially stronger second half to the year, supported by market share gains, a growing order book and a robust pipeline of opportunities, as well as some early signs of improving business and consumer confidence. Q3 FY25/26 revenues were 2% ahead of the prior year, with an average monthly run-rate 8% ahead of H1 FY25/26. The order book at the end of March 2026 was 28% higher than March 2025, and 8% higher than December 2025.
eEnergy Group 5.85p £22.7m (EAAS.L)
The Energy-as-a-Service provider delivering funded energy infrastructure upgrades across multi-site portfolios, today announced a trading update on its Q1 2026 activities and an update to its revenue recognition policy in advance of completion of the audited results for the year ended 31 December 2025. The Group’s Q1-26 revenue is £11.0m, with an adjusted EBITDA of £0.7m. The forward contracted order book was £10.7m (as at 31 March 2026). MACE (GB Energy) installations across 73 schools are largely completed and on track for completion by 31 May 2026. The Group now expects to report record H1-26 revenues of circa £24.0m (H1-25: £10.1m), in line with management expectations underpinned by circa £21m of revenue already delivered or contracted to be delivered.
Narf Industries 0.575p £9.8m (NARF.L)
The U.S.-based cybersecurity group specialising in advanced threat intelligence and resilient software security, provided a trading update for the year ended 31 March 2026. The unaudited FY26 revenue was approximately $4.2m, compared to $3.0m in FY25 driven by momentum within the group’s Government Research and Development activities. The group improved its forward revenue visibility with approximately $5.3m of 26/27 revenue in place across several contracts. During the period, the Group completed the rebranding of Ranger.ai to UPxi, reflecting its evolution into an Agentic AI platform focused on upstream intelligence for open source software, enabling early detection of cybersecurity risk at source before downstream impact.
Oriole Resources 0.35p £17.1m (ORR.L)
The AIM quoted gold exploration and development company focused on Central and West Africa, provided an update on its 90% owned Eastern Central Licence Package permits in Cameroon, which comprises four licences: Ndom, Pokor, Niambaram, and Tenekou. The Eastern CLP is contiguous with the Company's Mbe licence where the Company has recently reported a total Inferred Mineral Resource of 1.23Moz gold. Oriole has conducted a range of exploration programmes across its Ndom, Pokor and Niambaram licences within the Eastern CLP. The recent selective rock-chip sampling at Ndom has returned gold grades of up to 17.00g/t Au, related to NW-trending quartz veins that show similarities with mineralisation observed at the Company's Mbe project. Follow-up exploration is being planned.
Premier Miton Group 40.5p £63.8m (PMI.L)
The fund today provided an update on its unaudited statement of Assets under Management for the second quarter of the current financial year ending 30 September 2026. Total assets under Management was £9bn as at 31 March 2026, compared to £10.3bn on 30 September 2025 after continued net outflows and a challenging market environment, with £443m of net outflows for the quarter. The group is resetting costs and simplifying the business, delivering £2.5m of ongoing administration cost savings, expected to be fully implemented on a run-rate basis by September 2026. The closing cash position as at 31 March 2026 was £24.6m.
Strip Tinning Holdings 24.5p £4.5m (STG.L)
The UK based supplier of specialist connection systems for battery modules and automotive glazing applications, updates regarding its three major nominations. In the Battery Technologies division, the company received a formal serial order for the Zoox Robotaxi Cell Contacting systems. The Glazing Connectors division is ramping up with the first of the Company’s major smart-glass roof connectors contracts now in serial production on the Porsche Cayenne Electric and an Audi SUV model. The second major smart-glass roof connectors contract for the Mercedes CLA is progressing well with serial production being brought forward from Q3 to Q2 2026.
TheraCryf 0.235p £5.1m (TCF.L)
The biotech company developing new medicines for addiction and other neuropsychiatric disorders announced that it has filed a new process patent covering novel aspects of the manufacturing method for its lead programme, a selective orexin-1 receptor antagonist being developed for addiction. The patent, when granted, will protect for 20 years from filing, potentially to 2046, extends the commercial exclusivity for the Ox-1 blocker across major markets, substantially beyond the life of the existing global Composition of Matter patent. The filing follows recent successful manufacturing optimisation and scale-up work during which several novel and efficiency-enhancing chemical process improvements were identified.
Union Jack Oil 3.5p £5.1m (UJO.L)
The UK and USA focused onshore hydrocarbon, production, development, exploration and investment company, announces that, following the update on 8 April 2026, Reach Oil and Gas Company Inc., has informed the Company that there has been a short delay to the spud date for the Crossroads well, located in Southern Oklahoma, USA as a result of rig maintenance requirements. The Operator is confident that the well will be spudded before the end of April 2026. Union Jack currently holds a 43% interest. The Company's share of the drilling costs have already been funded from the Company's existing cash resources.
Verici Dx 0.55p £8.3m (VRCI.L)
The developer of advanced clinical diagnostics for organ transplant, provided a trading update for the three months ended 31 March 2026. Tutivia testing volumes increased quarter-on-quarter by 32% to 392 (Q4 '25: 296), significantly ahead of management expectations while year-on-year Q1 testing volumes were up 34% (Q1 '26 vs Q1 '25). The average reimbursement rate remains in line with management expectations. Seven new transplant centres ordered tests during the first quarter of the new financial year, and a second centre now includes Tutivia in its clinical protocols for patients during their treatment pathway.
Zinc Media 41p £10.33m (ZIN.L)
The television and content production group reports finals to December 2025. Revenue increased 28% to £41.5m but with a 4% decline in gross profit margins. The EBITDA improved to £1.9m from £1.5m and the statutory loss before tax increased by £1.2m to £2.6m. The Group had cash of £3.5m at 31 December 2025 (FY24: £6.3m). Middle East revenue grew 70% to £8.5m with total international revenues up 20% to £18.m. The Group is targeting a further £1m of annualised savings during FY26. The launch of Zinc Distribution in October 2025 is set to drive long term high-margin revenue from global programme and format sales. There is a highly advanced pipeline alongside acquisitive opportunities and with a growing base of owned IP, a clear growth strategy the CEO is confident of making progress.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
